Bridging gaps across the CLL care pathway – Part 1: From Signal to Stratification
By Léon Van Wouwe, Clinical Innovation Director, Volv Global From Signal to Stratification – Reimagining Early CLL Care through Algorithmic
By Léon Van Wouwe, Clinical Innovation Director, Volv Global From Signal to Stratification – Reimagining Early CLL Care through Algorithmic
By Léon Van Wouwe, Clinical Innovation Director, Volv Global A Hidden Cancer in Plain Sight Multiple myeloma (MM) has
By Léon Van Wouwe, Clinical Innovation Director, Volv Global Introduction: The Urgency of Early Diagnosis in Type 1 Diabetes
By Léon Van Wouwe, Clinical Innovation Director, Volv Global Recently, I had powerful thought come to me on reading
By Léon Van Wouwe, Clinical Innovation Director, Volv Global Emerging artificial intelligence solutions offer promising strategies to address critical
By Léon Van Wouwe, Clinical Innovation Director, Volv Global New data from Roche’s Itovebi (inavolisib) combined with Pfizer’s Ibrance
By Léon Van Wouwe, Clinical Innovation Director, Volv Global Introduction Progressive Pulmonary Fibrosis (PPF) is a severe clinical condition
By Léon Van Wouwe, Clinical Innovation Director, Volv Global Gastric (stomach) cancer remains a formidable global health challenge, ranking
By Christopher Rudolf, Volv Global An AI Methodology for Finding Patients with Rare Diseases: Volv Global’s inTrigue Finding patients with
